Valuation: Santhera Pharmaceuticals Holding AG

Market Cap 223M 267M 239M 202M 382M 25.56B 384M 2.68B 1.05B 13.19B 1B 982M 42.44B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 243M 292M 261M 221M 416M 27.88B 419M 2.93B 1.15B 14.39B 1.1B 1.07B 46.3B EV / Sales 2026 *
2.57x
EV / Sales 2027 * 2.05x
Free-Float
84.95%
Yield 2026 *
-
Yield 2027 * -
1 day+2.10%
1 week-5.81%
Current month-5.94%
1 month-7.49%
3 months-4.20%
6 months-12.38%
Current year+15.71%
1 week 14.04
Extreme 14.04
15.3
1 month 14.04
Extreme 14.04
16.28
Current year 11.7
Extreme 11.7
18.84
1 year 9.38
Extreme 9.38
18.84
3 years 7.21
Extreme 7.21
18.84
5 years 5
Extreme 5
20.3
10 years 5
Extreme 5
820
Manager TitleAgeSince
Chief Executive Officer 50 2026-07-14
Director of Finance/CFO 51 2025-02-23
Chief Operating Officer 55 2022-08-31
Director TitleAgeSince
Chairman 64 2022-06-29
Director/Board Member 58 2017-04-03
Director/Board Member 47 2023-06-26
Date Insider Type Main position Quantity % Market Cap. Importance
1/22/24 Buy 30,228 0.2396%
7/6/23 Buy 2,000 0.0016%
1/11/22 Buy 30,000 0.0549%
Change 5-day change 1-year change 3-year change Capi.($)
+2.10%-5.81%+40.73%+94.66% 263M
+0.28%+3.46%+41.89%+93.71% 1,051B
+0.88%+4.27%+38.28%+68.70% 630B
+1.68%+5.78%+21.96%+89.56% 489B
-0.10%+4.24%+69.15%+40.41% 359B
+0.61%+3.18%+24.05%+42.46% 344B
+0.72%+2.99%+14.29%+34.71% 272B
+0.23%+2.23%-5.91%+8.15% 246B
+0.65%+3.62%+43.93%+46.50% 224B
-0.49%+4.01%+28.38%+95.97% 187B
Average +0.60%+2.24%+31.67%+61.48% 380.4B
Weighted average by Cap. +0.41%+3.17%+34.07%+66.93%

Financials

2026 *2027 *
Net sales 94.7M 113M 102M 85.9M 162M 10.85B 163M 1.14B 446M 5.6B 426M 417M 18.01B 116M 138M 124M 105M 198M 13.24B 199M 1.39B 544M 6.83B 520M 509M 21.98B
Net income - -
Net Debt 20.3M 24.33M 21.78M 18.41M 34.73M 2.33B 34.95M 244M 95.5M 1.2B 91.38M 89.35M 3.86B 13.4M 16.06M 14.37M 12.15M 22.92M 1.53B 23.07M 161M 63.04M 792M 60.32M 58.98M 2.55B
Projected Income Statement - Annual - Santhera Pharmaceuticals Holding AG
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Date Price Change Volume
26-10-12 CHF 14.58 +2.10% 27,118
26-10-09 CHF 14.28 +0.99% 52,127
26-10-08 CHF 14.14 -3.68% 94,070
26-10-07 CHF 14.68 -3.80% 112,805
26-10-06 CHF 15.26 -1.42% 77,318
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Ratings Surperformance© - Santhera Pharmaceuticals Holding AG
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.58CHF
Average target price
27.50CHF
Spread / Average Target
+88.61%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Santhera Pharmaceuticals Holding AG
  1. Stock Market
  2. Stocks
  3. SANN Stock